. 2019 Oct 3;10(23):5722–5726. doi: 10.7150/jca.33605

Table 2.

Stratification analysis of LIG3 gene polymorphisms with neuroblastoma susceptibility

Variables	rs1052536 (cases/controls)		AOR (95% CI) ^a	P^a	rs4796030 (cases/controls)		AOR (95% CI) ^a	P ^a	Risk genotypes (cases/controls)		AOR (95% CI) ^a	P ^a
	CC/CT	TT			AA/AC	CC			0	1-2
Age, month
≤18	158/350	11/40	0.60 (0.30-1.20)	0.151	140/311	29/79	0.81 (0.50-1.29)	0.366	18/40	151/350	0.97 (0.54-1.75)	0.920
>18	265/555	35/53	1.38 (0.88-2.17)	0.162	238/479	62/129	0.96 (0.68-1.34)	0.792	27/76	273/532	1.48 (0.93-2.35)	0.101
Gender
Females	178/376	18/38	1.00 (0.56-1.80)	1.000	157/323	39/91	0.88 (0.58-1.34)	0.551	21/53	175/361	1.23 (0.72-2.10)	0.455
Males	245/529	28/55	1.10 (0.68-1.78)	0.697	221/467	52/117	0.94 (0.66-1.36)	0.751	24/63	249/521	1.25 (0.76-2.04)	0.382
Sites of origin
Adrenal gland	143/905	19/93	1.31 (0.77-2.22)	0.314	132/790	30/208	0.87 (0.57-1.33)	0.515	11/116	151/882	1.81 (0.95-3.44)	0.072
Retroperitoneal	126/905	12/93	0.91 (0.49-1.71)	0.773	111/790	27/208	0.93 (0.59-1.45)	0.743	15/116	123/882	1.06 (0.60-1.87)	0.846
Mediastinum	113/905	8/93	0.69 (0.33-1.46)	0.329	96/790	25/208	0.98 (0.61-1.56)	0.923	17/116	104/882	0.82 (0.47-1.42)	0.475
Others	34/905	6/93	1.68 (0.69-4.11)	0.256	33/790	7/208	0.80 (0.35-1.84)	0.599	1/116	39/882	5.09 (0.69-37.39)	0.110
Clinical stages
I+II+4s	216/905	17/93	0.76 (0.44-1.30)	0.320	195/790	38/208	0.74 (0.50-1.08)	0.114	21/116	212/882	1.33 (0.82-2.17)	0.249
III+IV	189/905	27/93	1.40 (0.88-2.22)	0.151	165/790	51/208	1.18 (0.83-1.68)	0.359	24/116	192/882	1.05 (0.66-1.68)	0.839

AOR, adjusted odds ratio; CI, confidence interval.

^a Adjusted for age and gender, omitting the corresponding stratification factor.